VOLUME 32 䡠 NUMBER 33 䡠 NOVEMBER 20 2014

JOURNAL OF CLINICAL ONCOLOGY

C O R R E S P O N D E N C E

Reply to A. Soultati et al

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

We have read with interest the comment from Soultati et al1 in reference to the randomized phase II study of onartuzumab in combination with erlotinib in patients with advanced non–small-cell lung cancer (NSCLC).2 Soultati et al recognize that MET inhibition may not be best assessed using traditional response criteria and suggest reviewing our data to better define the pattern of disease progression. If progression was primarily due to new sites of distant disease and not growth of baseline lesions, this might potentially account for the low objective response rate observed in our study. A review of the imaging data from computed tomography scanning does not identify any differences in the proportion or patterns of disease progression between treatment arms. Since the phase II publication, the results of a recently completed phase III trial of onartuzumab and erlotinib in patients with advanced MET-positive NSCLC have been presented.3 Unfortunately there was no advantage for onartuzumab in terms of survival, progression-free survival, or response. Although this trial did not replicate the phase II results, targeting MET may still prove to be a useful strategy in more defined patient populations in which this is a key oncogenic driver of disease.

David Robert Spigel Sarah Cannon Research Institute

Amy Christian Peterson Medivation Services

Although all authors completed the disclosure declaration, the following author(s) and/or an author’s immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors. Employment or Leadership Position: Amy Christian Peterson, Medivation (C) Consultant or Advisory Role: David Robert Spigel, Genentech (U) Stock Ownership: Amy Christian Peterson, Genentech Honoraria: None Research Funding: None Expert Testimony: None Patents, Royalties, and Licenses: None Other Remuneration: None REFERENCES 1. Soultati A, Josephs DH, Spicer JF: Effect of onartuzumab added to erlotinib on metastasis in patients with lung cancer. J Clin Oncol 32:3781, 2014 2. Spigel DR, Ervin TJ, Ramlau RA, et al: Randomized phase II Trial of onartuzumab in combination with erlotinib in patients with advanced non-smallcell lung cancer. J Clin Oncol 31:4105-4114, 2013 3. Spigel DR, Edelman MJ, O’Byrne K, et al: Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol 32:506s, 2014 (suppl 15s; abst 8000)

DOI: 10.1200/JCO.2013.54.9683; published online ahead of print at www.jco.org on October 20, 2014 ■ ■ ■

Journal of Clinical Oncology, Vol 32, No 33 (November 20), 2014: pp 3781-3782

© 2014 by American Society of Clinical Oncology

Downloaded from jco.ascopubs.org on March 7, 2015. For personal use only. No other uses without permission. Copyright © 2014 American Society of Clinical Oncology. All rights reserved.

3781

Reply to A. Soultati et Al.

Reply to A. Soultati et Al. - PDF Download Free
44KB Sizes 2 Downloads 4 Views